Akeega 100 mg/500 mg film-coated tablets
*Company:
Janssen Sciences Ireland (a Johnson & Johnson Company)Status:
No Recent UpdateLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 22 August 2024
File name
EN-Akeega 100mg_500mg film coated tablets-20240711-PIL-II0003-Clean-EDMS-RIM-500117_24.0.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
Section 2 has been updated as follows:
....• blood clots in the lungs or legs, or have had them in the past.
....
If you develop low abnormal blood-cell counts for a long period of time while taking Akeega, this may be a sign of more serious problems with the bone marrow such as ‘myelodysplastic syndrome’ (MDS) or ‘acute myeloid leukaemia’ (AML). Your doctor may want to test your bone marrow to check for these problems.
Section 4
Multiple updates to 'Other side effects' sub section.
EMEA/H/C/005932/II/0003 - Magnitude Final Clinical Study Report
Updated on 22 August 2024
File name
EN-Akeega-20240711-SPC-clean_approved.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 4.2 - editorial change
Section 4.4 has been updated as follows:
....Marked increases in liver enzymes leading to treatment interruption or discontinuation occurred in clinical studies, although these were uncommon (see section 4.8). Serum aminotransferase and total bilirubin levels should be measured prior to starting treatment, every two weeks for the first three months of treatment, and monthly thereafter for the first year and then every other month for the duration of treatment.
....
In the MAGNITUDE study, Nno cases of MDS/AML have been observed in patients treated with 200 mg of niraparib and 1000 mg of abiraterone acetate plus prednisone or prednisolone.
Section 4.8 and 5.1
Multiple changes to this section - see SPC.
EMEA/H/C/005932/II/0003 - Magnitude Final Clinical Study Report
Updated on 26 October 2023
File name
IE-Akeega-SPC-Clean-approved.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 26 October 2023
File name
IE-Akeega-SPC-Clean-approved.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 26 October 2023
File name
IE-Akeega-SPC-Clean-approved.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 26 October 2023
File name
Akeega 100 mg500 mg PIL.pdf
Reasons for updating
- New PIL for new product
Updated on 26 October 2023
File name
Akeega 100 mg500 mg PIL.pdf
Reasons for updating
- New PIL for new product
Updated on 26 October 2023
File name
Akeega 100 mg500 mg PIL.pdf
Reasons for updating
- New PIL for new product